Ireland - English - HPRA (Health Products Regulatory Authority)

le vet beheer b.v. - thiamazole - film-coated tablet - 2.5 mg/tablet - thiamazole - cats - miscellaneous

Ireland - English - HPRA (Health Products Regulatory Authority)

le vet beheer b.v. - thiamazole - film-coated tablet - 5 mg/tablet - thiamazole - cats - miscellaneous

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 1000 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; hypromellose; crospovidone; mannitol; purified talc; titanium dioxide; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; titanium dioxide; magnesium stearate; iron oxide yellow; purified talc; crospovidone; povidone; hypromellose - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; microcrystalline cellulose; povidone; mannitol; crospovidone; hypromellose; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; povidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hyprolose; sodium starch glycollate type a; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; microcrystalline cellulose; propylene glycol; magnesium stearate; titanium dioxide; lactose monohydrate; sunset yellow fcf aluminium lake; sodium lauryl sulfate; purified talc; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; maize starch; microcrystalline cellulose; hypromellose; purified talc; propylene glycol; sodium lauryl sulfate; iron oxide red; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.